This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Proton RT for the Treatment of Pediatric Rhabdomyosarcoma

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2017 by Torunn Yock, MD, Massachusetts General Hospital
Sponsor:
Collaborators:
M.D. Anderson Cancer Center
Brigham and Women's Hospital
Boston Children’s Hospital
Dana-Farber Cancer Institute
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Torunn Yock, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00592592
First received: December 28, 2007
Last updated: March 2, 2017
Last verified: March 2017
December 28, 2007
March 2, 2017
October 2004
June 2020   (Final data collection date for primary outcome measure)
Late toxicity [ Time Frame: 4 years ]
Frequency and severity of late complications from irradiation using proton beam therapy in place of conventional photon beam therapy in pediatric patients with pediatric rhabdomyosarcomas.
To assess late complications from irradiation using proton beam therapy in place of conventional photon beam therapy in pediatric patients with pediatric rhabdomyosarcomas. [ Time Frame: 4 years ]
Complete list of historical versions of study NCT00592592 on ClinicalTrials.gov Archive Site
  • Acute toxicity [ Time Frame: 4 years ]
    Frequency and severity of acute side effects from irradiation using proton beam therapy in this patient population.
  • Dosimetric comparison [ Time Frame: 4 years ]
    Comparison of Dose distribution to tumor and surrounding normal structures using DVH's generated from the proton plan used to treat the patient and the photon plan generated for comparison purposes.
  • Local Control [ Time Frame: 4 years ]
    Rates of local control using proton radiotherapy.
  • To assess acute side effects from irradiation using proton beam therapy in this patient population. [ Time Frame: 4 years ]
  • To compare dose distribution to tumor and surrounding normal structures using DVH's generated from the proton plan used to treat the patient and the photon plan generated for comparison purposes. [ Time Frame: 4 years ]
  • To monitor the rates of local control using proton radiotherapy. [ Time Frame: 4 years ]
Not Provided
Not Provided
 
Proton RT for the Treatment of Pediatric Rhabdomyosarcoma
A Phase II Trial of Proton RT for the Treatment of Pediatric Rhabdomyosarcoma
The main purpose of this study is to see if using proton beam radiation therapy instead of photon beam radiation therapy can reduce side effects from radiation treatment for rhabdomyosarcoma. Photon beam radiation is the standard type of radiation for treating most rhabdomyosarcoma and many other types of cancer. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor, then leaves the body through healthy tissue. A beam of proton radiation enters the body and passes through healthy tissue, encounters tumor, but then stops. This means that less healthy tissue is affected by proton beam radiation than by photon beam radiation.
  • A special device is made for each participant to help them hold still during the treatment. This may be in the form of a mask or a custom made foam cradle depending on the area to be treated.
  • Radiation treatments will be given once per day, 5 days a week for a total of 4 to 6 weeks, depending upon how much total dose the tumor requires.
  • Participants will be seen once per week by their radiation doctor to monitor health and record any side effects from treatment.
  • After the radiation treatments are completed, participants will be required to undergo further tests and evaluations for several years following treatment.
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Rhabdomyosarcoma
Radiation: Proton Beam Radiation
Once per day, 5 days a week for a total of 4 to 6 weeks.
Experimental: Proton Beam Radiation
Proton Beam Radiation
Intervention: Radiation: Proton Beam Radiation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
110
June 2020
June 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with biopsy proven newly diagnosed rhabdomyosarcoma.
  • Patients less than or equal to 21 years of age.
  • Patients must be treated with a standardly accepted chemotherapy regimen.
  • May not have metastatic disease unless aged 2-10 with embryonal histology.
  • Must be willing to receive follow-up care for a minimum of five years after treatment at MGH and annual visits unless it is too difficult to return to MGH for follow-up care. In that event, they must be willing to have their outside medical information released to us to track the results.
  • Timing of radiation must be according to the IRB protocol upon which the patient is treated within either 35 days of last chemotherapy or surgery.

Exclusion Criteria:

  • Life expectancy of less than 2 years.
  • Co-morbidities that would make the use of radiation too toxic to deliver safely, such as serious local injury or collagen vascular disease.
  • Patients who are pregnant
  • Previous treatment with radiation therapy.
Sexes Eligible for Study: All
up to 21 Years   (Child, Adult)
No
Contact: Torunn Yock, MD 617-724-1836
United States
 
 
NCT00592592
04-188
P01CA021239 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
Torunn Yock, MD, Massachusetts General Hospital
Massachusetts General Hospital
  • M.D. Anderson Cancer Center
  • Brigham and Women's Hospital
  • Boston Children’s Hospital
  • Dana-Farber Cancer Institute
  • National Institutes of Health (NIH)
  • National Cancer Institute (NCI)
Principal Investigator: Torunn Yock, MD Massachusetts General Hospital
Massachusetts General Hospital
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP